Analyst Report: CHRW
1. EXECUTIVE SUMMARY
C.H. Robinson fell 11.14% to $127.60 on Wednesday October 28, 2026, after a quarter whose headline numbers beat. The brief points to a concern about claims costs, which FreightWaves says Landstar raised with its own results on Tuesday afternoon. Cash from operations fell, operating expenses rose 10.6%, and TD Cowen cut its target on margin concerns. Peers UPS, FDX and EXPD each moved by less than 1.3% over the same period, which points to a stock-specific reaction with a read-through from Landstar. The brief does not isolate a single intraday trigger, so the weight each factor carried is inference. The pending $5.8bn RXO acquisition and the pause in buybacks add balance-sheet pressure to a stock that is down 21.19% year to date.
2. THE CATALYST
Results came out before the open on October 28. Yahoo Finance and Investing.com report adjusted EPS of $1.80 against a $1.75 consensus, and revenue of $5.36bn against $4.92bn expected. The facts panel carries a different consensus (EPS $1.61, revenue $4.51bn). Both sets of estimates sit below the reported figures, so the quarter beat on either basis.
Yahoo Finance reports a pre-market dip of only about 1.8%, so most of the decline came after the open. The session opened at $133.18, hit a low of $125.61 and closed at $127.60 on volume of 4,785,300 shares, 2.87 times the 50-session average.
FreightWaves (via Yahoo Finance) says Landstar opened the claims concern with its results on Tuesday, October 27, and that both companies were marked down despite strong numbers. An editor's note on that article corrects its earlier wording: the companies reported higher claims, not higher insurance premiums. CHRW closed up 2.45% on October 27, before its own report.
The Business Wire release gave bears further material. Cash from operations fell $151.3m to $124.1m, which the company attributed to working capital tied to higher transportation rates. Operating expenses rose 10.6% to $536.6m. Simply Wall St headlined the day as results clashing with liability fears.
TD Cowen cut its target to $145 from $152 and kept Hold, citing margin concerns (Investing.com, October 28).
| Date | Close | Change | Event |
|---|---|---|---|
| Oct 27 | $143.59 | +2.45% | Landstar reports after the close of the session's main trading, per FreightWaves |
| Oct 28 | $127.60 | -11.14% | CHRW results, claims concern, TD Cowen cut |
3. COMPANY PROFILE
C.H. Robinson is an integrated freight and logistics company in the industrials sector with two segments, North American Surface Transportation and Global Forwarding. It sells truckload, less-than-truckload brokerage and intermodal services. The market capitalisation is $14.73bn, with a forward P/E of 17.1, a trailing P/E of 27.4 and a dividend yield of 1.76%.
Per Business Wire, the quarter showed:
- North American Surface Transportation volume up about 3.5% year over year, against a 0.3% decline in the Cass Freight Shipment Index, the 14th straight quarter of outgrowth.
- Truckload adjusted gross profit per shipment up 17.0%.
- Income from operations up 23.1% to $271.8m and adjusted operating income up 26.1% to $290.8m.
- Adjusted diluted EPS of $1.80, up 28.6%.
GuruFocus reports that management has put share repurchases on hold to reduce leverage. On October 5 the company agreed to buy RXO for $5.8bn, or $30.25 per share (TipRanks via CNN), and projects $300m in net synergies (GuruFocus). Competitors named in the facts panel's peer group are UPS, FedEx and Expeditors.
4. DEEP DIVE ANALYSIS
Do fundamentals justify the move? Operating results were strong: volume outgrew the market, profit per truckload shipment rose and adjusted operating income grew 26.1%. The weaker items were the $151.3m fall in operating cash flow and the 10.6% rise in operating expenses, and the claims theme that Landstar had already raised. An 11.14% fall on a beat suggests investors were pricing in margin and liability risk that the headline numbers do not show. That is inference, since the brief does not quantify the claims impact on CHRW.
Comparable episodes. TipRanks headlines recorded CHRW falling roughly 10% to 14% intraday on October 5 when the RXO deal was announced, although these are headline snapshots and not confirmed closes. Analyst cuts clustered in late July, when Baird and TD Cowen lowered targets (Benzinga, July 28), and Simply Wall St notes pointed to liability risk then too. Claims and liability have been a recurring theme, so the October 28 reaction continues an existing narrative.
Analyst backdrop. Targets were already falling before the report:
| Firm | Action | Date |
|---|---|---|
| JPMorgan | Target to $198 from $225, Overweight | Oct 5 |
| Evercore ISI | Target to $217 from $237, Outperform | Oct 6 |
| Truist | Target to $200 from $215, Buy | Oct 7 |
| BMO Capital | Target to $160 from $190, Market Perform | Oct 16 |
| TD Cowen | Target to $145 from $152, Hold | Oct 28 |
MarketBeat carried a headline that Deutsche Bank lowered its rating to Hold on October 12, which the research assistant did not open. Simply Wall St says the average target was trimmed by $4.83, citing RXO leverage, expected dilution and insurance and liability costs.
Peers. UPS fell 0.44%, FDX 0.82% and EXPD 1.25% over the period, and the S&P 500 rose 0.28%. The brief found no sourced news explaining those peer moves. Landstar is the only sourced read-through.
Bull case. Volume growth above the market, rising truckload profit per shipment and a truck market the release describes as still tightening on supply support earnings. At 17.1 times forward earnings, the stock trades below its trailing multiple of 27.4, and RXO synergies of $300m would add to profit if delivered.
Bear case. Claims costs may keep rising across brokers, cash flow weakened, buybacks have stopped and the RXO purchase adds leverage and dilution. Analysts have been cutting targets for weeks.
5. TECHNICAL SNAPSHOT
The close of $127.60 sits below the 50-day average of $145.85 and the 200-day average of $168.98, and 39.07% under the 52-week high of $209.43 set on 2026-07-22. It is 2.14% above the 52-week low of $124.93 from 2025-10-29, and the session low of $125.61 stayed above that level. Some headlines claim a new 52-week low, which the facts panel does not support. Volume of 4,785,300 was 2.87 times the 50-session average, the heaviest in the table, and the close is the lowest in the ten-session table, so no support level can be named from those closes. The 52-week low of $124.93 is the nearest reference point below. The nearest resistance is $138.85, the October 19 close, with the gap-up area near the $143.59 pre-report close above that.
6. RISK FACTORS
- Further claims or liability cost disclosures from CHRW or other brokers.
- Margin pressure, which TD Cowen cited, and the 10.6% rise in operating expenses.
- Weaker operating cash flow as higher transportation rates absorb working capital.
- RXO integration, leverage and dilution, with buybacks on hold. The brief found no sourced date for the RXO shareholder vote or closing, so no dated catalyst is listed.
- Further target cuts or rating downgrades after the report.
- Source gaps: the Q3 transcript and the full FreightWaves article were not opened, so the claims explanation rests on snippets.
The next earnings date in the facts panel is the October 28 report that has just passed, so no later date is available.
7. ACTIONABLE OUTLOOK
Short term (1-2 weeks). The stock closed at a one-year-low area after heavy volume. Price action will turn on whether it holds above the $124.93 52-week low and on any further analyst revisions. A rebound toward $138.85 would need evidence that claims costs are contained. A close below $124.93 would put the stock at a new 52-week low.
Medium term (1-3 months). Direction depends on quantified claims costs, progress on the RXO transaction and any resumption of buybacks. Analyst targets from $145 (TD Cowen) to $217 (Evercore ISI) leave a wide range of views.
Long term. The brief shows market-beating volume growth and rising operating income, so the operating thesis is intact. The balance sheet and liability risk are now larger parts of it, with the RXO deal adding leverage. This is analysis only and not personal financial advice.